Zheng Xing Xing Ye Ri Bao·2025-11-28 09:08Core Insights - The biopharmaceutical sector experienced a slight increase of 0.09% on November 28, with Rongchang Biopharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] Biopharmaceutical Sector Performance - Rongchang Biopharmaceutical (688331) closed at 99.70, with a rise of 3.85% and a trading volume of 71,200 shares, amounting to a transaction value of 708 million yuan [1] - Wanzhe Co., Ltd. (000534) saw a closing price of 20.53, increasing by 2.80% with a trading volume of 121,900 shares, totaling 248 million yuan [1] - Kanghua Biopharmaceutical (300841) closed at 81.81, up 2.10%, with a trading volume of 25,700 shares and a transaction value of 208 million yuan [1] - Other notable performers included Nearshore Protein (688137) at 42.25 (+1.81%), and Wofoo Biopharmaceutical (300357) at 31.49 (+1.68%) [1] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 533 million yuan from institutional investors, while retail investors contributed a net inflow of 300 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Kanghong Pharmaceutical (002773) experienced a net inflow of 4.21 million yuan from institutional investors, while it faced a net outflow of 4.38 million yuan from speculative funds [3] - Notable net inflows from retail investors were observed in stocks like Nuozhilan (920047) with 2.51 million yuan, while stocks like Baik Biopharmaceutical (688276) faced net outflows from retail investors [3]